SSG
DFTX

Summit Securities Group’s Definium Therapeutics DFTX Stock Holding History

Summit Securities Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,096
Closed -$20.1K – 1239
2025
Q2 		$20.1K Sell
3,096
-10,815
-78% -$71.1K ﹤0.01% 727
2025
Q1 		$81.4K Buy
+13,911
New +$99.6K 0.01% 252
2021
Q3 		– Sell
-667
Closed -$35K – 818
2021
Q2 		$35K Buy
+667
New +$35K ﹤0.01% 682

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Summit Securities Group's DFTX Position: Q3 2025 in Review

Summit Securities Group sold out of Definium Therapeutics (DFTX) in Q3 2025, closing a stake of 3,096 shares — an estimated $20.1K sold.

Summit Securities Group first reported a position in DFTX in Q2 2021 and held it in 3 quarters. The position peaked at $81.4K in Q1 2025. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

  • Summit Securities Group reported no remaining Definium Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 3,096 Definium Therapeutics shares in Q3 2025, an estimated $20.1K.
  • Summit Securities Group first reported a position in Definium Therapeutics in Q2 2021 and held it in 3 quarters.
  • Summit Securities Group's Definium Therapeutics position peaked at $81.4K in Q1 2025.
  • 195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.